Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary R MacVicar

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Clinical Genitourinary Cancer|July 16, 2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808Bradley C Carthon, Se Eun Kim, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
European Urology|July 6, 2023
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
Cancer|May 8, 2014
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinomaMaha Hussain, Stephanie Daignault, Neeraj Agarwal, et al.
JAMA Network Open|October 7, 2024
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate CancerAmir Goldkorn, Catherine Tangen, Melissa Plets, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2021
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)Amir Goldkorn, Catherine Tangen, Melissa Plets, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 17, 2013
Prostate cancer, version 1.2014James L Mohler, Philip W Kantoff, Andrew J Armstrong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 8, 2012
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelinesJames L Mohler, Andrew J Armstrong, Robert R Bahnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0Sonam Puri, Natasha B Leighl, Nofisat Ismaila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0Joshua E Reuss, Lyudmila Bazhenova, Nofisat Ismaila, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical Genitourinary Cancer|July 16, 2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808Bradley C Carthon, Se Eun Kim, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
European Urology|July 6, 2023
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
Cancer|May 8, 2014
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinomaMaha Hussain, Stephanie Daignault, Neeraj Agarwal, et al.
JAMA Network Open|October 7, 2024
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate CancerAmir Goldkorn, Catherine Tangen, Melissa Plets, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2021
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)Amir Goldkorn, Catherine Tangen, Melissa Plets, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 17, 2013
Prostate cancer, version 1.2014James L Mohler, Philip W Kantoff, Andrew J Armstrong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 8, 2012
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelinesJames L Mohler, Andrew J Armstrong, Robert R Bahnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0Sonam Puri, Natasha B Leighl, Nofisat Ismaila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0Joshua E Reuss, Lyudmila Bazhenova, Nofisat Ismaila, et al.
Pageof 2